Valeant Hit With Shareholder Suit Over $3B Biovail Deal
By Jacqueline Bell ( July 19, 2010, 3:45 PM EDT) -- Valeant Pharmaceuticals International Inc. and its directors have been hit with a shareholder class action seeking to block the company's $3.2 billion deal to merge with Biovail Corp....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.